PMC:7299399 / 23466-23789 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T105","span":{"begin":207,"end":214},"obj":"Body_part"}],"attributes":[{"id":"A105","pred":"fma_id","subj":"T105","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":" the rare possibility of reversion to a pathogenic form able to cause infection. Vaccine candidates based in this application have previously been designed for SARS-CoV with high stability.72,73 Recombinant-protein vaccines and inactivated vaccines are safer but might require adjuvants to increase their immunogenicity. In"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T81","span":{"begin":70,"end":79},"obj":"Disease"},{"id":"T82","span":{"begin":160,"end":168},"obj":"Disease"}],"attributes":[{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":" the rare possibility of reversion to a pathogenic form able to cause infection. Vaccine candidates based in this application have previously been designed for SARS-CoV with high stability.72,73 Recombinant-protein vaccines and inactivated vaccines are safer but might require adjuvants to increase their immunogenicity. In"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T237","span":{"begin":38,"end":39},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":" the rare possibility of reversion to a pathogenic form able to cause infection. Vaccine candidates based in this application have previously been designed for SARS-CoV with high stability.72,73 Recombinant-protein vaccines and inactivated vaccines are safer but might require adjuvants to increase their immunogenicity. In"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T147","span":{"begin":114,"end":125},"obj":"Chemical"},{"id":"T148","span":{"begin":207,"end":214},"obj":"Chemical"},{"id":"T149","span":{"begin":277,"end":286},"obj":"Chemical"}],"attributes":[{"id":"A147","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"},{"id":"A148","pred":"chebi_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A149","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"}],"text":" the rare possibility of reversion to a pathogenic form able to cause infection. Vaccine candidates based in this application have previously been designed for SARS-CoV with high stability.72,73 Recombinant-protein vaccines and inactivated vaccines are safer but might require adjuvants to increase their immunogenicity. In"}

{"project":"LitCovid-sentences","denotations":[{"id":"T98","span":{"begin":81,"end":320},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" the rare possibility of reversion to a pathogenic form able to cause infection. Vaccine candidates based in this application have previously been designed for SARS-CoV with high stability.72,73 Recombinant-protein vaccines and inactivated vaccines are safer but might require adjuvants to increase their immunogenicity. In"}

{"project":"LitCovid-PubTator","denotations":[{"id":"347","span":{"begin":160,"end":168},"obj":"Species"},{"id":"351","span":{"begin":70,"end":79},"obj":"Disease"}],"attributes":[{"id":"A347","pred":"tao:has_database_id","subj":"347","obj":"Tax:694009"},{"id":"A351","pred":"tao:has_database_id","subj":"351","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" the rare possibility of reversion to a pathogenic form able to cause infection. Vaccine candidates based in this application have previously been designed for SARS-CoV with high stability.72,73 Recombinant-protein vaccines and inactivated vaccines are safer but might require adjuvants to increase their immunogenicity. In"}

{"project":"2_test","denotations":[{"id":"32519842-26513244-158495","span":{"begin":189,"end":191},"obj":"26513244"},{"id":"32519842-25609816-158496","span":{"begin":192,"end":194},"obj":"25609816"}],"text":" the rare possibility of reversion to a pathogenic form able to cause infection. Vaccine candidates based in this application have previously been designed for SARS-CoV with high stability.72,73 Recombinant-protein vaccines and inactivated vaccines are safer but might require adjuvants to increase their immunogenicity. In"}